The COVID-19 vaccine, developed by Pfizer / Biotech, is safe and effective in protecting children from 5 to 11 years of age. 

This was stated in a statement issued by Albert Borla, Chairman, and CEO of Pfizer

Pfizer vaccine
Photo Credits by 

“We want to protect children from the vaccine and are awaiting regulatory approval, especially at a time when the corona-type delta is spreading rapidly among children and poses a threat to them,” he said. 

He said that since July, there has been a 240% increase in the number of cases of COVID-19 in children in the United States, which necessitates vaccination. 

Pfizer recruited 2,268 children between the ages of 5 and 11. 

These children were given 2 doses of the Pfizer vaccine but their doses were kept lower than those 12 years of age or older. 

The company said that in the trial, the vaccine proved safe, tolerable in children aged 5 to 11 years, while it also produced a solid antibody reaction that neutralizes the virus. 

The data will now be shared by Pfizer and BioNTech with the US Food and Drug Administration (FDA), the European Medicines Agency, and other regulators, and an application for emergency use approval will be submitted to the United States. 

The FDA has already given full approval to the Pfizer vaccine for people 16 years of age or older, while emergency approval has been obtained for 12 to 15 years. 

“The results of the trial are a solid basis for approving the vaccination of children between the ages of 5 and 11, and we will soon approach regulators for approval,” Pfizer chairman said. 

Pfizer / Bio-Tech is also conducting vaccine trials on children aged 2 to 5 years and children aged 6 months to 2 years, the results of which could be released sometime this year. 

Pfizer has been approved in the United States for the use of a third dose of the vaccine for people 12 years of age and older, and this booster dose will be for people with weakened immune systems. 

But the FDA rejected the government’s plan to provide a booster dose for all, saying the third dose should now be given to people 65 or older. In which there is a risk of serious severity of COVID-19